Analysis of Market Access Agreements in Turkey
DOI:
https://doi.org/10.7175/fe.v21i1.1457Keywords:
Market access, Risk-sharing agreements, ReimbursementAbstract
BACKGROUND: Reimbursement agencies are increasingly adopting innovative reimbursement approaches for new and expensive technologies. Social Security Institution (SSI), Turkey`s reimbursement agency, established the Alternative Reimbursement Commission (ARC) on February 10, 2016. This study aimed to understand the implementations of market access agreements in recent years in Turkey.
METHODS: Decisions of the Health Services Pricing Commission published in the official gazette , and information from the Turkey Pharmaceuticals and Medical Devices Agency, the Abroad Drug List, Health Implementation Communique published by SSI with additional lists, such as the Annex-4A List of Reimbursed Medicines and the Annex-4C Abroad Drug Price List, were used. The data was transferred to Windows Office Excel files, and a descriptive analysis was conducted and evaluated by two market access experts.
RESULTS: There were 57 drugs included in the coverage of reimbursement with alternative reimbursement since the application was started in Turkey. 35 of them were added to Annex-4A and 22 of them to Annex-4C. Furthermore, 45.6% of the drugs had an Anatomic Therapeutic Chemical Classification (ATC) code of l-antineoplastic and immunomodulating agents, 28% were orphan drugs, 44 of them had a confidential discount rate, and financial-based agreement models were preferred for nearly all agreements.
CONCLUSIONS: Turkey has been implementing market access agreements since mid-2016. In the past 3 years, 57 drugs have been covered for reimbursement under the new implementation. Further analysis should be conducted to understand the decision-making process involved.
References
Ministry of Health of the Republic of Turkey. Health Transformation Programme 2001. Available at https://sbu.saglik.gov.tr/Ekutuphane/Yayin/133 (last accessed May 2019)
Tanios N, Wagner M, Tony M, et al. Which criteria are considered in healthcare decisions? Insights from an international survey of policy and clinical decision-makers. Int J Technol Assess 2013; 29: 456-65; https://doi.org/10.1017/S0266462313000573
Maynard A, Bloor K. Dilemmas in the regulation of the market for pharmaceuticals. Health Affair 2003; 22: 31-41; https://doi.org/10.1377/hlthaff.22.3.31
Italian Trade Agency. Electro Medicals Market in Turkey. BKP Research&Consulting, 2016. Available at http://www.farexport.it/wp-content/uploads/2016/03/Elettromedicale-in-Turchia.pdf (last accessed May 2019)
Commission of the European Communities. Safe, innovative, and accessible medicines: A renewed vision for the pharmaceutical sector. Brussels: Commission of the European Communities. 2008
Belloni A, Morgan D, Paris V. Pharmaceutical expenditure and policies: Past trends and future challenges (Report Id: 87). Paris: OECD Publishing, 2016
Bang H, Zhao H. Median-Based Incremental Cost-Effectiveness Ratio (ICER). J Stat Theory Pract 2012; 6: 428-42; https://doi.org/10.1080/15598608.2012.695571
Şentürk A. The effect of drug reimbursement policies on drug expenditures in the Social Security System. (Master Dissertation). Retrieved from Ulusal Tez Merkezi. 227923: 50-80
Fefer E. Pharmaceutical legislation and regulation. In: Embrey MA, editor. Managing access to medicines and health technologies. Sterling, Virginia: Kumarian Press, 2012. p. 100-120.
Embrey MA. Managing access to medicines and health technologies. 3rd ed. Sterling, Virginia: Kumarian Press, 2012
Drummond MF, Schwartz JS, Jönsson B, et al. Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess 2008; 24: 244-58; https://doi.org/10.1017/S0266462308080343
Uğurlu M. Evaluation of health technologies and their role in the drug market access process. In: Kahveci R editor. Drug and market access process. Ankara, Türkiye: SAGE Yayıncılık, 2017. p. 59-85
Toumi M, Jaroslawski S. Introduction to the Market Access. In. Koçkaya G, Wertheimer A, editors. Pharmaceutical market access in emerging markets. Turin: Seed, 2016. p. 3-20; https://doi.org/10.7175/747.ch1
Koçkaya G, Kılıç P. Pharmaceutical policies and market access. ISPOR Connections. 2012;1-3
Kahveci R. Drug and market access process. 1st ed. Ankara: SAGE Yayıncılık, 2017
Koçkaya G. Introduction to market access. 2018. Available at http://sepd.org.tr/wp-content/uploads/2018/01/G%C3%BCven%C3%A7-Ko%C3%A7kaya-Pazar-Eri%C5%9Fime-Giri%C5%9F-v2.ppt (last accessed May 2019)
Cook JP, Vernon JA, Manning R. Pharmaceutical risk-sharing agreements. Pharmacoeconomics 2008; 26: 551-6; https://doi.org/10.2165/00019053-200826070-00002
Carone G, Schwierz C, Xavier A. Cost-containment policies in public pharmaceutical spending in the EU (Rapor No:461). Brussels: European Commission, 2012; https://doi.org/10.2139/ssrn.2161803
Kharvi S, Pakkala TPM, Srinivasan G. Ordering policies under currency risk-sharing agreements: A Markov chain approach. Opsearch 2019; 1-20; https://doi.org/10.1007/s12597-019-00394-z
Koçkaya G. Value-based pricing within drug pricing methods. In: Kahveci R, editor. Drug and market access process. Ankara, Türkiye: SAGE Yayıncılık, 2017. p. 126-133.
OECD. Pensions at a Glance 2017: OECD and G20 Indicators. Paris: OECD Publishing, 2017. p. 122-3
Ferrario A, Kanavos P. Managed entry agreements for pharmaceuticals: The European experience. LSE. 2013. Available at http://eprints.lse.ac.uk/50513/ (last accessed May 2019)
Carlson JJ, Sullivan SD, Garrison LP, et al. Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy 2010; 96: 179-90; https://doi.org/10.1016/j.healthpol.2010.02.005
Dinç M. Overview of pharmaceutical reimbursement system in Turkey and evaluation of transition process to alternative reimbursement models. (Master Dissestation). Retrieved from Ulusal Tez Merkezi. 489688: 16-43
Lorente R, Antonanzas F, Rodriguez-Ibeas R. Implementation of risk-sharing contracts as perceived by Spanish hospital pharmacists. Health Economics Review 2019; 9: 25; https://doi.org/10.1186/s13561-019-0242-x
Garrison Jr LP, Towse A, Briggs A, et al. Performance-based risk-sharing arrangements-good practices for design, implemention, and evaluation: Report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health 2013; 16: 703-19; https://doi.org/10.1016/j.jval.2013.04.011
Beykoz V. Performance-based models. In: Kahveci R, editor. Drug and market access process. Ankara, Türkiye: SAGE Yayıncılık, 2017. p. 141-7
Walker S, Sculpher M, Claxton K, et al. Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions. CHE Research Paper 77. Center for Health Economics. 2012; https://doi.org/10.1016/j.jval.2011.12.013
Walker S, Sculpher M, Claxton K, et al. Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions. CHE Research Paper 77. University of York: Centre for Health Economics, 2012. Available at https://www.york.ac.uk/media/che/documents/papers/researchpapers/CHERP77_a_framework_for_coverage_decisions_only_in_research_evidence_development.pdf (last accessed May 2019)
Medicare’s Coverage With Evidence Development: A Policy-Making Tool in Evolution. J Oncol Pract 2007; 3: 296-301; https://doi.org/10.1200/JOP.0763501
Espin J, Rovira J, Garcia L. Experiences and impact of European risk-sharing schemes focusing on oncology medicines. Brussels: Commissioned by the European Commission, Directorate-General Enterprise, 2011
Vitry A, Roughead E. Managed entry agreements for pharmaceutical in Australia. Health Policy 2014; 117: 345-52; https://doi.org/10.1016/j.healthpol.2014.05.005
Dokuyucu Ö. Financial-based models. In: Kahveci R, editor. Drug and market access process, Ankara, Türkiye: SAGE Yayıncılık, 2017. p. 148-52
Vogler S, Zimmermann N, Habl C, et al. Discounts and rebates granted to public payers for medicines in European countries. Southern Med Review 2012; 5: 38-46; https://doi.org/10.2174/1876824520130426001
Demir C. Evaluation of the views and preferences of stakeholders on the drug policies implemented in Turkey by using the Multi-Criteria Decision Making Method (ELECTRE III). (Master Dissestation). Retrieved from Ulusal Tez Merkezi. 509928:65-82
Official Gazette. Social Security Institution General Health Insurance Alternative Reimbursement Regulation. 2016. Number: 29620. Available at http://www.resmigazete.gov.tr/eskiler/2016/02/20160210-6.htm (last accessed Apr 2019)
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)
